A Phase 1/1b, Open-Label, Dose-Escalation and Expansion

Project: Research project

Project Details

Description

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
StatusActive
Effective start/end date2/1/173/28/22

Funding

  • IGNYTA, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.